A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Sponsor

NextCure, Inc. (Industry)

Overall Status

Withdrawn

CT.gov ID

NCT04430933

Collaborator

(none)

Enrollment

Arms

10.8

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy

Condition or Disease	Intervention/Treatment	Phase
Advanced or Metastatic Solid Tumors Non-Small Cell Lung Cancer	Drug: NC318 Drug: Pemetrexed/Carboplatin Drug: Nab paclitaxel/Carboplatin Drug: Docetaxel	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1/2 Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Anticipated Study Start Date :

Dec 6, 2021

Anticipated Primary Completion Date :

Jun 30, 2022

Anticipated Study Completion Date :

Oct 30, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: NC318 + Pemetrexed/Carboplatin NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with pemetrexed/carboplatin	Drug: NC318 NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle Drug: Pemetrexed/Carboplatin Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
Experimental: NC318 + Nab-paclitaxel/carboplatin NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Nab-paclitaxel/carboplatin	Drug: NC318 NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle Drug: Nab paclitaxel/Carboplatin Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
Experimental: NC318 + Docetaxel NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Docetaxel	Drug: NC318 NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle Drug: Docetaxel Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle

Arm

Intervention/Treatment

Experimental: NC318 + Pemetrexed/Carboplatin

NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with pemetrexed/carboplatin

Drug: NC318

NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle

Drug: Pemetrexed/Carboplatin

Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle

Experimental: NC318 + Nab-paclitaxel/carboplatin

NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Nab-paclitaxel/carboplatin

Drug: NC318

NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle

Drug: Nab paclitaxel/Carboplatin

Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle

Experimental: NC318 + Docetaxel

NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Docetaxel

Drug: NC318

NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle

Drug: Docetaxel

Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle

Outcome Measures

Primary Outcome Measures

Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0 [14 months]
Frequency, duration, and severity of treatment-emergent adverse events (AEs)

Secondary Outcome Measures

Objective Response Rate per RECIST [14 months]
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1
Duration of Response per RECIST [14 months]
Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1
Disease Control Rate per RECIST [14 months]
Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1
Progression-Free Survival per RECIST [14 months]
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1
Overall Survival per RECIST [14 months]
Overall Survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1
Maximum Plasma Concentration (Cmax) of NC318 [14 months]
To evaluate the Maximum Plasma Concentration (Cmax) of NC410

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Men and women aged 18 or older.
Willingness to provide written informed consent for the study.
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
Have a life expectancy of at least 6 months
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Disease progression after receipt of a prior systemic immunotherapy such as monoclonal antibodies targeting PD-1, PD-L1, CTLA-4 or other immune modulators with or without chemotherapy.
Presence of measurable disease based on RECIST v1.1. Tumor lesions - situated in a previously irradiated area, or in an area subjected to other locoregional therapy, are not considered measurable unless there has been demonstrated progression in the lesion.
After dose escalation, subject must be willing to undergo pretreatment and on-treatment tumor biopsies (core or excisional). Note: A baseline biopsy obtained for other purposes (i.e., not an NC318-02 study procedure) before signing consent may be utilized if the subject has not had any intervening systemic therapy from the time of the biopsy to the start of treatment with the medical monitor's approval.
Female subjects of childbearing potential (defined as women who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy and are not postmenopausal, defined as ≥ 12 months of amenorrhea) must have a negative serum pregnancy test at screening. All female and male subjects of childbearing potential must agree to take appropriate precautions to avoid pregnancy or fathering children (with at least 99% certainty) from screening through 60 days after the last dose of study drug.

Exclusion Criteria:

Inability to comprehend or unwilling to sign the Informed Consent Form.
Received more than 1 prior line of systemic anti-cancer therapy for Stage IIIB/IIIc/IV or recurrent NSCLC disease (does not include adjuvant or neoadjuvant treatments).
Requires concurrent radiation or other anticancer therapy
Screening laboratory values of:

Absolute neutrophil count < 1.5 × 10^9/L
Platelets < 100 × 10^9/L
Hemoglobin < 9 g/dL or < 5.6 mmol/L
Serum creatinine > 1.5 × institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2.5 × ULN
Total bilirubin ≥ 1.5 × ULN unless conjugated bilirubin ≤ ULN (conjugated bilirubin only needs to be tested if total bilirubin exceeds ULN). If there is no institutional ULN, then direct bilirubin must be < 40% of total bilirubin.
International normalized ratio (INR) or prothrombin time (PT) > 1.5 × ULN
Activated partial thromboplastin time (aPTT) > 1.5 × ULN

Transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before the first administration of study drug.
Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study drug:
≤ 21 days for chemotherapy or radiation therapy. Subjects must also not require chronic use of corticosteroids and must not have had radiation pneumonitis because of a treatment. A 1-week washout is permitted for palliative radiation to non-central nervous system (CNS) disease with medical monitor approval. Note: Bisphosphonates and denosumab are permitted medications.
≤ 7 days for immune-suppressive-based treatment for any reason. Note: Use of inhaled or topical steroids or corticosteroid use for radiographic procedures is permitted. Note: The use of physiologic corticosteroid replacement therapy may be approved after consultation with the medical monitor.
≤ 28 days or 5 half-lives (whichever is longer) for prior ICI.
Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy. Note: Subjects with stable chronic conditions (≤ Grade 2) not expected to resolve (such as neuropathy and alopecia) are exceptions and may enroll. Note: Subjects with a history of any grade immune-related ocular AE (e.g., episcleritis, scleritis, uveitis) will be excluded. Note: Subjects with a history of a Grade 3 or higher immune-related AE from prior immunotherapies are excluded.
History of recurrent Grade 2 pneumonitis attributed to prior treatment with immune checkpoint inhibitor therapy
Receipt of a live vaccine within 30 days of planned start of study therapy. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
Active autoimmune disease that required systemic treatment in the past (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Subjects who have not required systemic treatment in the past 2 years may be eligible with approval of the medical monitor. Note: Subjects with hyper/ hypothyroidism are eligible to participate. Note: Replacement and symptomatic therapies (e.g., levothyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered a form of systemic immune suppressive therapy and are allowed.
Known active CNS metastases and/or carcinomatous meningitis. Note: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 28 days before the first dose of study drug and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases or CNS edema, and have not required steroids for at least 7 days before the first dose of study drug.
Known concurrent malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry apart from cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the subject has been disease-free for > 1 year, after treatment with curative intent.
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.
Active infection requiring systemic therapy.
Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation. HBV-DNA and HCV-RNA must be undetectable. Subjects cannot be positive for HBV-DNA, HCV-RNA, hepatitis B surface antigen, or anti-hepatitis B core antibody. Note: Subjects with no prior history of hepatitis B infection who have been vaccinated against hepatitis B and who have a positive antibody against hepatitis B surface antigen test as the only evidence of prior exposure may participate in the study.
Known history of HIV (HIV 1 or HIV 2 antibodies).
Known allergy or reaction to any component of study drug or formulation components.
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 60 days after the last dose of study treatment.